SM

 

HeadLice.Org Hot Spots
 
NCBI PubMed
                 
 
 
               
  back to About Entrez
back to About Entrez


 
1: Fam Pract 2003 Jan;20(1):61-8  

Influences on general practitioners' decision to prescribe new drugs-the importance of who says what.

Prosser H, Almond S, Walley T.

Prescribing Research Group, Department of Pharmacology and Therapeutics, The Infirmary, 70 Pembroke Place, Liverpool L69 3GF and Royal Liverpool University Hospital, Liverpool L7 8XP, UK.

OBJECTIVES: The aim of this study was to understand the range of factors that influence general practitioners' uptake of new drugs METHODS: A total of 107 general practitioners selected purposively from high, medium and low new drug prescribing practices in two health authorities in the north west of England were interviewed using the critical incident technique with semi-structured interviews. Interview topics included reasons for prescribing new drugs launched between January 1998 and May 1999; reasons for prescribing the new drug rather than alternatives; and sources of information used for each prescribed drug. RESULTS: Important biomedical influences were the failure of current therapy and adverse effect profile. More influential than these, however, was the pharmaceutical representative. Hospital consultants and observation of hospital prescribing was cited next most frequently. Patient request for a drug, and patient convenience and acceptability were also likely to influence new drug uptake. Written information was of limited importance except for local guidelines. general practitioners were largely reactive and opportunistic recipients of new drug information, rarely reporting an active information search. The decision to initiate a new drug is heavily influenced by 'who says what', in particular the pharmaceutical industry, hospital consultants and patients. The decision to 'adopt' a new drug is clinched by subsequent personal clinical experience. CONCLUSIONS: Prescribing of new drugs is not simply related to biomedical evaluation and critical appraisal but, more importantly, to the mode of exposure to pharmacological information and social influences on decision making. Viewed within this broad context, prescribing variation becomes more understandable. Findings have implications for the implementation of evidence-based medicine, which requires a multifaceted approach.

PMID: 12509373 [PubMed - in process]
        
   

 

-- send this page to a friend --

The National Pediculosis Association,® Inc.
A Non-Profit Organization
Serving The Public Since 1983.

The National Pediculosis Association is a non-profit, tax exempt
organization that receives no government or agency funding.
Contributions are tax-deductible under the 501c(3) status.

© 1997-2009 The National Pediculosis Association®, Inc. All images © 1997-2009 The National Pediculosis Association®, Inc.